Tag:
regorafenib
Latest Headlines
Latest Headlines
Buzz: Is Bayer looking to buy Onyx Pharma?
Reuters reported today that Bayer is looking to close a multibillion-euro acquisition deal, quoting sources who say that an announcement could be "imminent."
Bayer bolsters blockbuster case for regorafenib with new PhIII data
Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.
Bayer details positive PhIII data on cancer blockbuster hopeful regorafenib
Bayer HealthCare took another step toward a planned marketing application for the cancer drug regorafenib today as it unveiled the late-stage colorectal cancer data that it plans to take to
Onyx Pharma CFO plugs cancer pipeline amid rumored sales process
Onyx Pharmaceuticals' ( $ONXX ) financial chief rattled off the reasons why the cancer drug company would make a nice buyout option in an interview with Bloomberg, walking a fine line by declining to
Bayer predicts blockbuster success for four of its late-stage drugs
You can count Bayer among the Big Pharma companies unwilling to back down from their multibillion-dollar gambles on drug research. The company boldly predicted that four of its late-stage programs
Onyx Pharma shares soar on report of its hunt for options, acquirers
A report about Onyx Pharmaceuticals' ( $ONXX ) search for business alternatives such as a company sale has generated buzz in the biotech world. Bloomberg reported Monday afternoon that the South San
Bayer and new partner Onyx crow over PhIII regorafenib success
Just two weeks after Bayer opted to settle a simmering legal spat with Onyx ( $ONXX ) over the rights to the late-stage cancer drug regorafenib, investigators published a set of positive data for the
Bayer settles Onyx spat with $160M payout, sales rights and royalties
Longtime partners Onyx Pharmaceuticals and Bayer have patched up a long-running dispute over who owns the rights to a Phase III cancer drug that bears a close resemblance to the blockbuster Nexavar
Bayer's regorafenib gets orphan drug designation
Bayer HealthCare Pharmaceuticals' investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by
Ignoring lawsuit, Bayer takes regorafenib into PhIII cancer study
Germany's Bayer Schering Pharma is marching ahead into a Phase III study of regorafenib for colorectal cancer, gambling that it can successfully fend off a legal attack from its U.S. partner Onyx.
